| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Rush Ryan Bradford | 5.1% | $3,055,500 | 1,050,000 | Rush Ryan Bradford | 17 Dec 2024 | |||
| BlackRock, Inc. | 2% | $895,288 | 414,485 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Adverum Biotechnologies, Inc. - Common Stock, $0.0001 par value per share (ADVM). This represents 0% of the company’s total 22,107,985 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$47,605,774 | $4.36 | 0 |
| 2025 Q3 | 13,566,970 | $61,458,813 | +$897,363 | $4.53 | 48 |
| 2025 Q2 | 13,503,213 | $29,035,276 | -$9,430,367 | $2.15 | 57 |
| 2025 Q1 | 15,830,355 | $67,598,655 | +$2,134,875 | $4.37 | 69 |
| 2024 Q4 | 15,367,331 | $71,762,612 | -$19,025,186 | $4.67 | 66 |
| 2024 Q3 | 16,433,840 | $116,616,020 | +$7,083,173 | $7.02 | 74 |
| 2024 Q2 | 14,520,480 | $99,630,518 | +$7,101,493 | $6.86 | 64 |
| 2024 Q1 | 13,170,929 | $186,240,391 | +$186,240,391 | $14.14 | 56 |